BioMarin updates financial impact of Inozyme Pharma acquisition with estimated 221 million charge in Q3 2025
I'm PortAI, I can summarize articles.
BioMarin Pharmaceutical Inc. anticipates a charge of approximately $221 million in Q3 2025 due to its acquisition of Inozyme Pharma, Inc. on July 1, 2025. This charge is expected to affect both GAAP and Non-GAAP diluted earnings per share by about $1.10 each. The figures are preliminary and subject to final financial statement procedures for the quarter ending September 30, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments